Nasus Pharma Ltd. ((NSRX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Nasus Pharma Ltd. is conducting a clinical study titled ‘Efficacy and Safety of FMXIN002 Epinephrine Powder Nasal Spray for the Treatment of Acute Allergic Reactions in Patients at Risk of Anaphylaxis.’ The study aims to evaluate the effectiveness of FMXIN002, a powder-based intranasal epinephrine spray, in treating anaphylaxis. This research is significant as it explores a potentially quicker and more convenient alternative to traditional intramuscular epinephrine injections.
Intervention/Treatment: The study tests two interventions: FMXIN002, an epinephrine 4mg nasal powder spray, and a traditional adrenaline 0.5mg injectable product. FMXIN002 is designed to offer a rapid and easy-to-administer treatment for acute allergic reactions.
Study Design: This interventional study follows a randomized, parallel assignment model with quadruple masking. The primary purpose is treatment, ensuring unbiased results by masking participants, care providers, investigators, and outcomes assessors.
Study Timeline: The study began on June 8, 2025, with the latest update submitted on June 26, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: The successful development of FMXIN002 could positively impact Nasus Pharma’s stock performance by introducing a novel treatment option in the anaphylaxis market. This could shift investor sentiment favorably, especially if the product demonstrates superior efficacy or convenience over existing treatments. Competitors in the allergy treatment industry may need to innovate in response to this potential new entrant.
The study is ongoing, with further details available on the ClinicalTrials portal.